Bausch + Lomb Corporation announced the acquisition of Trukera Medical, a United States-based ophthalmic medical diagnostic company, according to a press release. Trukera Medical, previously owned by AccelMed Partners and other shareholders, is known for its ScoutPro device, which measures the osmolarity of tears, a key indicator of dry eye disease.
This acquisition aims to enhance Bausch + Lomb’s surgical capabilities in the United States and strengthen its position in managing dry eye conditions. ScoutPro is valued for its ability to detect hyperosmolarity, which can affect surgical outcomes if untreated.
“As a global leader in dry eye disease management, as well as cataract and refractive medical devices and implants, we’re uniquely positioned to optimize pre-surgical preparation to help ensure positive post-surgical outcomes,” said Luc Bonnefoy, president, Surgical, Bausch + Lomb. “ScoutPro has already become a valuable preoperative diagnostic tool for many U.S. surgeons, and with our scale we believe it can have an even greater impact.”
Read the full press release here.
Related Content
